Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Li Xie, Li Zhang, Hui Chen, Yong-Yu Yang, Jian Wu

Clin Mol Hepatol. 2024;30(2):279-280. Published online March 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0191

View: 968 Download: 32 Crossref: 1

Special topic: Alcoholic liver diseases The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Yuchen Liu, Xiaohui Wang, Yingzi Yang

Clin Mol Hepatol. 2020;26(4):742-750. Published online September 28, 2020

DOI: https://doi.org/10.3350/cmh.2020.0178

View: 7477 Download: 200 Web of Science: 35 Crossref: 33

David Tornai, Gyongyi Szabo

Clin Mol Hepatol. 2020;26(4):686-696. Published online September 28, 2020

DOI: https://doi.org/10.3350/cmh.2020.0145

View: 5931 Download: 219 Web of Science: 15 Crossref: 15

1 |

Viewed By 5424	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5394	MAFLD: How is it different from NAFLD?
Viewed By 5289	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3951	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3944	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 77	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 68	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 52	MAFLD: How is it different from NAFLD?

Search